JPH09504941A - ニワトリ貧血症ウイルス変異体およびワクチン、ならびにウイルスタンパク質vp1、vp2およびvp3またはウイルスをコードする配列に基づくそれらのための用途 - Google Patents
ニワトリ貧血症ウイルス変異体およびワクチン、ならびにウイルスタンパク質vp1、vp2およびvp3またはウイルスをコードする配列に基づくそれらのための用途Info
- Publication number
- JPH09504941A JPH09504941A JP7505072A JP50507295A JPH09504941A JP H09504941 A JPH09504941 A JP H09504941A JP 7505072 A JP7505072 A JP 7505072A JP 50507295 A JP50507295 A JP 50507295A JP H09504941 A JPH09504941 A JP H09504941A
- Authority
- JP
- Japan
- Prior art keywords
- cav
- cells
- virus
- dna
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725585 Chicken anemia virus Species 0.000 title claims abstract description 231
- 241000700605 Viruses Species 0.000 title claims abstract description 29
- 229960005486 vaccine Drugs 0.000 title abstract description 12
- 210000004027 cell Anatomy 0.000 claims abstract description 150
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 93
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 87
- 108020004414 DNA Proteins 0.000 claims abstract description 74
- 208000015181 infectious disease Diseases 0.000 claims abstract description 53
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 19
- 230000006907 apoptotic process Effects 0.000 claims abstract description 16
- 230000030833 cell death Effects 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 6
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 241000287828 Gallus gallus Species 0.000 claims description 51
- 241000701447 unidentified baculovirus Species 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000053602 DNA Human genes 0.000 claims description 13
- 241000238631 Hexapoda Species 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 208000007502 anemia Diseases 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 244000144977 poultry Species 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 108010067390 Viral Proteins Proteins 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 46
- 230000003472 neutralizing effect Effects 0.000 abstract description 34
- 230000006698 induction Effects 0.000 abstract description 10
- 230000001717 pathogenic effect Effects 0.000 abstract description 6
- 230000002458 infectious effect Effects 0.000 abstract description 3
- 238000001415 gene therapy Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000003302 anti-idiotype Effects 0.000 abstract 1
- 238000003149 assay kit Methods 0.000 abstract 1
- 229960004854 viral vaccine Drugs 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 85
- 235000013330 chicken meat Nutrition 0.000 description 48
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 44
- 101710132601 Capsid protein Proteins 0.000 description 43
- 101710197658 Capsid protein VP1 Proteins 0.000 description 43
- 101710108545 Viral protein 1 Proteins 0.000 description 43
- 230000008774 maternal effect Effects 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 20
- 239000006166 lysate Substances 0.000 description 18
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 15
- 239000000427 antigen Substances 0.000 description 15
- 230000003053 immunization Effects 0.000 description 15
- 238000001890 transfection Methods 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000001541 thymus gland Anatomy 0.000 description 11
- 235000013601 eggs Nutrition 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000005534 hematocrit Methods 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 239000013592 cell lysate Substances 0.000 description 9
- 238000010166 immunofluorescence Methods 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 230000001640 apoptogenic effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 101710182846 Polyhedrin Proteins 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000002969 egg yolk Anatomy 0.000 description 5
- 230000006882 induction of apoptosis Effects 0.000 description 5
- 101150066555 lacZ gene Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 101100278318 Dictyostelium discoideum dohh-2 gene Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 101710121537 mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000002992 thymic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000212384 Bifora Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical class ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- IXQPRUQVJIJUEB-UHFFFAOYSA-N 7-(diethylamino)-n-[2-(2,5-dioxopyrrol-1-yl)ethyl]-2-oxochromene-3-carboxamide Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C=C1C(=O)NCCN1C(=O)C=CC1=O IXQPRUQVJIJUEB-UHFFFAOYSA-N 0.000 description 1
- 241001103870 Adia Species 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101710136297 Protein VP2 Proteins 0.000 description 1
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 1
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101100024330 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MSB1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 241001504592 Trachurus trachurus Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- JLQUFIHWVLZVTJ-UHFFFAOYSA-N carbosulfan Chemical compound CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 JLQUFIHWVLZVTJ-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 101150061458 cav gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 231100001021 decreased hematocrit Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.自然環境から遊離された、ニワトリ貧血症ウイルスに由来し、図1、図2 または図3のうちの1つの少なくとも一部分を含んで成り、かつニワトリ貧血症 ウイルスに対してアポプトシスを誘発することができるか、または直接あるいは 間接酌に抗体を産生することができることを特徴とするポリペプチド。 2.アポプトシスを誘発する能力を減少させる変異がその中で提供されている 請求項1記載のポリペプチド。 3.ニワトリ貧血症ウイルス感染予防用組成物であり、少なくとも請求項1ま たは2記載のポリペプチドとアジュバントとを含んで成ることを特徴とする組成 物。 4.請求項1または2記載の1種以上のポリペプチドをコードすることを特徴 とする組換えDNA分子。 5.図1、図2または図3の核酸配列の鎖の1本の少なくとも一部分を含んで 成るか、あるいは図1、図2または図3の核酸配列の鎖の1本の少なくとも一部 分を含んで成るDNA分子と、厳酷な条件下でハイブリダイズする請求項4記載 のDNA分子。 6.少なくとも請求項2または5記載のDNA分子と発現のための公知の制御 因子とを含んで成ることを特徴とするベクタ。 7.ウイルスに由来する請求項6記載のベクタ。 8.レトロウイルスに由来する請求項7記載のベクタ。 9.少なくとも部分的にバキュロウイルスに由来する請求項6記載のベクタ。 10.生きたウイルスベクタに由来する請求項6記載のベクタ。 11.請求項4または5記載の他のDNA分子を、第2のDNA分子として含ん で成る請求項6〜10のいずれかに記載のベクタ。 12.キメラタンパク質をコードする請求項6〜10のいずれかに記載のベクタ 。 13.請求項6〜12のいずれかに記載のベクタでトランスフェクトされたこと を特徴とする宿主細胞。 14.請求項9記載のベクタでトランスフェクトされたことを特徴とする昆虫細 胞。 15.請求項10記載のベクタとアジュバントとを含んで成ることを特徴とする 家禽類でのニワトリ貧血症予防用組成物。 16.少なくとも1つのウイルスタンパク質をコードするDNA中に、アポプト シスを誘発する能力が減少されるような変異を有することを特徴とする末端が切 り取られたニワトリ貧血症ウイルス。 17.前記変異は、図8bのポリペプチドの11C末端アミノ酸をウイルスが発 現しないような変異である請求項16記載のウイルス。 18.請求項16または17記載のウイルスとアジュバントとを含んで成ること を特徴とする家禽類でのニワトリ貧血症感染予防用組成物。 19.請求項1または2記載のポリペプチドに対して指向することを特徴とする 抗体、その誘導体またはその断片。 20.少なくとも請求項1または2記載のポリペプチドと、検出用の試薬とを含 んで成ることを特徴とするニワトリ貧血症ウイルスに対する抗体を検出する装置 。 21.少なくとも請求項19記載の抗体、その誘導体またはその断片と、検出用 の試薬とを含んで成ることを特徴とする請求項1記載のポリペプチド検出する装 置。 22.細胞死の誘発における請求項1記載のポリペプチドの用途。 23.腫瘍の治療における請求項1記載のポリペプチドの用途。 24.請求項4または5記載のDNA分子が腫瘍細胞中で発現されることを特徴 とする腫瘍の治療法。 25.前記DNA分子が、ウイルス性ベクタによって腫瘍細胞に導入される請求 項24記載の治療法。 26.前記DNA分子が、レセプタ仲介による取込みを経て腫瘍細胞に 導入される請求項24記載の治療法。 27.前記DNA分子がリポゾームによって腫瘍細胞に導入される請求項24記 載の治療法。 28.請求項1記載のポリペプチドと腫瘍に関連するタンパク質、糖質またはリ ン脂質に親和性を有する物質とを少なくとも含んで成ることを特徴とする腫瘍治 療のためのコンジュゲート。 29.腫瘍に親和性のある物質が抗体、その誘導体またはその断片である請求項 28記載のコンジュゲート。 30.DNAが直接、腫瘍に注射される請求項24の治療法。 31.DNAがエレクトロポレーションによって腫瘍細胞に導入される請求項2 4記載の治療法。 32.DNAがパーティクルボンバードメント(粒子爆撃)によって腫瘍細胞に 導入される請求項24記載の治療法。 33.少なくともポリペプチドが、パーティクルボンバートメント(粒子爆撃) によって腫瘍細胞に導入される請求項28および29記載の治療法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL9301272A NL9301272A (nl) | 1993-07-20 | 1993-07-20 | Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus. |
NL9301272 | 1993-07-20 | ||
PCT/NL1994/000168 WO1995003414A2 (en) | 1993-07-20 | 1994-07-19 | Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09504941A true JPH09504941A (ja) | 1997-05-20 |
JP3829290B2 JP3829290B2 (ja) | 2006-10-04 |
Family
ID=19862681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50507295A Expired - Lifetime JP3829290B2 (ja) | 1993-07-20 | 1994-07-19 | ニワトリ貧血症ウイルス変異体およびワクチン、ならびにウイルスタンパク質vp1、vp2およびvp3またはウイルスをコードする配列に基づくそれらのための用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5952002A (ja) |
EP (2) | EP1253201B1 (ja) |
JP (1) | JP3829290B2 (ja) |
AT (2) | ATE236980T1 (ja) |
AU (1) | AU703187B2 (ja) |
CA (1) | CA2167578C (ja) |
DE (2) | DE69432486T2 (ja) |
DK (2) | DK0784685T3 (ja) |
ES (2) | ES2311005T3 (ja) |
NL (1) | NL9301272A (ja) |
PT (2) | PT784685E (ja) |
WO (1) | WO1995003414A2 (ja) |
ZA (1) | ZA945275B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019514366A (ja) * | 2016-04-26 | 2019-06-06 | ロンドン スクール オブ ハイジーン アンド トロピカル メディシンLondon School Of Hygiene & Tropical Medicine | レオウイルス科ワクチン |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080234466A1 (en) * | 1990-09-12 | 2008-09-25 | Noteborn Mathieu H M | Delivery method for the tumor-specific apoptosis-inducing activity of apoptin |
US6162461A (en) * | 1990-09-12 | 2000-12-19 | Leadd B.V. | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor |
EP0878546A1 (en) * | 1997-04-15 | 1998-11-18 | Leadd B.V. | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin |
EP0872552A1 (en) * | 1997-04-15 | 1998-10-21 | Leadd B.V. | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin |
US5789567A (en) * | 1994-07-06 | 1998-08-04 | Cornell Research Foundation, Inc. | Chicken infectious anemia virus vaccine |
GB9414888D0 (en) * | 1994-07-23 | 1994-09-14 | Univ Belfast | Method and composition |
WO1996040931A1 (en) * | 1995-06-07 | 1996-12-19 | Aesculaap B.V. | Neutralizing conformational epitopes of chicken anemia virus |
AU718422B2 (en) * | 1995-06-07 | 2000-04-13 | Leadd B.V. | Methods and uses for apoptin |
EP0927757A1 (en) | 1997-12-03 | 1999-07-07 | Leadd B.V. | Methods and means for inducing apoptosis by interfering with Bip-like proteins |
US7361730B1 (en) * | 1999-03-15 | 2008-04-22 | University Of Maryland | Surface localized colligin/Hsp47 in carcinoma cells |
EP1199363A1 (en) * | 2000-10-20 | 2002-04-24 | Leadd B.V. | Phosphorylation modifications of apoptin |
AUPR567401A0 (en) * | 2001-06-14 | 2001-07-12 | University Of Melbourne, The | Circovirus vaccines |
HUE054868T2 (hu) | 2005-12-29 | 2021-10-28 | Boehringer Ingelheim Animal Health Usa Inc | Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására |
DK2371383T3 (en) | 2005-12-29 | 2015-11-30 | Boehringer Ingelheim Vetmed | Use of a PCV2 immunogenic composition for reduction of clinical symptoms in pigs |
CN102311928B (zh) * | 2011-08-25 | 2013-04-24 | 中国农业科学院哈尔滨兽医研究所 | 鸡贫血病毒vp1、vp2蛋白共表达的重组酵母工程菌、其构建方法及应用 |
BR112018007525A2 (pt) | 2015-10-16 | 2018-10-30 | Kansas State University Research Foundation | composições imunogênicas de circovírus suíno tipo 3 e métodos de produzir e usar as mesmas |
CN113980146B (zh) * | 2021-11-11 | 2022-09-27 | 扬州优邦生物药品有限公司 | 三聚体化鸭黄病毒E蛋白domainIII、其制备方法和运用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9002008A (nl) * | 1990-09-12 | 1992-04-01 | Stichting Centr Diergeneeskund | Recombinant dna en rna en daarvan afgeleide produkten. |
ZA918426B (en) * | 1990-10-31 | 1992-12-30 | Akzo Nv | Chicken anemia virus vaccine and diagnostic |
ZA927014B (en) * | 1991-09-20 | 1993-03-19 | Akzo Nv | Chicken anaemia agent vaccine. |
-
1993
- 1993-07-20 NL NL9301272A patent/NL9301272A/nl not_active Application Discontinuation
-
1994
- 1994-07-19 AT AT94925638T patent/ATE236980T1/de not_active IP Right Cessation
- 1994-07-19 PT PT94925638T patent/PT784685E/pt unknown
- 1994-07-19 WO PCT/NL1994/000168 patent/WO1995003414A2/en active IP Right Grant
- 1994-07-19 EP EP01205103A patent/EP1253201B1/en not_active Expired - Lifetime
- 1994-07-19 AU AU75473/94A patent/AU703187B2/en not_active Ceased
- 1994-07-19 ES ES01205103T patent/ES2311005T3/es not_active Expired - Lifetime
- 1994-07-19 PT PT01205103T patent/PT1253201E/pt unknown
- 1994-07-19 DE DE69432486T patent/DE69432486T2/de not_active Expired - Fee Related
- 1994-07-19 DK DK94925638T patent/DK0784685T3/da active
- 1994-07-19 ZA ZA945275A patent/ZA945275B/xx unknown
- 1994-07-19 JP JP50507295A patent/JP3829290B2/ja not_active Expired - Lifetime
- 1994-07-19 EP EP94925638A patent/EP0784685B1/en not_active Expired - Lifetime
- 1994-07-19 AT AT01205103T patent/ATE401406T1/de not_active IP Right Cessation
- 1994-07-19 DE DE69435117T patent/DE69435117D1/de not_active Expired - Fee Related
- 1994-07-19 CA CA002167578A patent/CA2167578C/en not_active Expired - Fee Related
- 1994-07-19 ES ES94925638T patent/ES2196032T3/es not_active Expired - Lifetime
- 1994-07-19 DK DK01205103T patent/DK1253201T3/da active
-
1997
- 1997-08-14 US US08/911,092 patent/US5952002A/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019514366A (ja) * | 2016-04-26 | 2019-06-06 | ロンドン スクール オブ ハイジーン アンド トロピカル メディシンLondon School Of Hygiene & Tropical Medicine | レオウイルス科ワクチン |
Also Published As
Publication number | Publication date |
---|---|
AU703187B2 (en) | 1999-03-18 |
EP1253201A2 (en) | 2002-10-30 |
ATE236980T1 (de) | 2003-04-15 |
ZA945275B (en) | 1995-02-24 |
PT1253201E (pt) | 2008-10-27 |
DE69432486D1 (de) | 2003-05-15 |
EP1253201A3 (en) | 2003-01-08 |
JP3829290B2 (ja) | 2006-10-04 |
WO1995003414A2 (en) | 1995-02-02 |
DE69435117D1 (de) | 2008-08-28 |
CA2167578C (en) | 2007-03-13 |
AU7547394A (en) | 1995-02-20 |
WO1995003414A3 (en) | 1995-03-02 |
ATE401406T1 (de) | 2008-08-15 |
DE69432486T2 (de) | 2004-03-04 |
DK1253201T3 (da) | 2008-11-17 |
EP0784685A2 (en) | 1997-07-23 |
ES2311005T3 (es) | 2009-02-01 |
EP1253201B1 (en) | 2008-07-16 |
US5952002A (en) | 1999-09-14 |
ES2196032T3 (es) | 2003-12-16 |
DK0784685T3 (da) | 2003-08-04 |
NL9301272A (nl) | 1995-02-16 |
PT784685E (pt) | 2003-08-29 |
EP0784685B1 (en) | 2003-04-09 |
CA2167578A1 (en) | 1995-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3829290B2 (ja) | ニワトリ貧血症ウイルス変異体およびワクチン、ならびにウイルスタンパク質vp1、vp2およびvp3またはウイルスをコードする配列に基づくそれらのための用途 | |
EP0755259B1 (en) | CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON | |
JP2703538B2 (ja) | 偽狂犬病ウイルス突然変異体、それを含有するワクチン、その生産法およびその使用法 | |
KR100204438B1 (ko) | 치킨 아네미아 바이러스 백신 및 진단방법 | |
CA2088599A1 (en) | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system | |
RU2146292C1 (ru) | Последовательность днк, гибридизационная проба, олигонуклеотид (варианты), вакцины, cav-белок (варианты), диагностические наборы и штамм e.coli | |
JPH08504096A (ja) | E型肝炎パキスタン株の組換えタンパク質ならびに診断法およびワクチンにおけるそれらの利用 | |
US6071520A (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor | |
KR101506979B1 (ko) | 전형적 돼지 콜레라 바이러스에 대한 키메릭 백신 항원 | |
AU2020103776A4 (en) | Koi herpesvirus (khv) orf-149-based carbon nanotube supported nucleic acid vaccine and application thereof | |
AU720640B2 (en) | Neutralizing conformational epitopes of chicken anemia virus | |
US6162461A (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor | |
US6217870B1 (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1 VP2 and VP3 or sequences of that virus coding therefor | |
US5789567A (en) | Chicken infectious anemia virus vaccine | |
Cain et al. | Temperature dependent characteristics of a recombinant infectious hematopoietic necrosis virus glycoprotein produced in insect cells | |
US5981502A (en) | Methods and compositions for inducing apoptosis in tumor cells | |
JP2905483B2 (ja) | 弱毒化ヘルペスウイルス及び外来性dnaを含むヘルペスウイルス | |
WO1996001116A9 (en) | Chicken infectious anemia virus vaccine | |
WO1994002613A1 (en) | Anti-feline immunodeficiency virus (fiv) vaccines | |
JP3428666B2 (ja) | 組換えマレック病ウイルスおよびその製法 | |
JPH05502166A (ja) | Aids、arcおよびhiv感染の治療および予防のための免疫治療用組成物 | |
MXPA97009851A (en) | Epithopes conformational neutralizers of poem anemia viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050921 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060315 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060516 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060627 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060630 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100721 Year of fee payment: 4 |